Advertisment
Indian Journal of Nephrology About us |  Subscription |  e-Alerts  | Feedback | Login   
  Print this page Email this page   Small font sizeDefault font sizeIncrease font size
 Home | Current Issue | Archives| Ahead of print | Search |Instructions |  Editorial Board  

Users Online:978

Official publication of the Indian Society of Nephrology
  Search
 
 ~ Next article
 ~ Previous article 
 ~ Table of Contents
  
 ~  Similar in PUBMED
 ~  Search Pubmed for
 ~  Search in Google Scholar for
 ~Related articles
 ~  Article in PDF (815 KB)
 ~  Citation Manager
 ~  Access Statistics
 ~  Reader Comments
 ~  Email Alert *
 ~  Add to My List *
* Registration required (free)  

 
   Abstract
   Introduction
   Case Reports
   Discussion
   Conclusion
   References
   Article Figures
   Article Tables

 Article Access Statistics
    Viewed4275    
    Printed160    
    Emailed3    
    PDF Downloaded283    
    Comments [Add]    
    Cited by others 5    

Recommend this journal

 


 
CASE REPORT
Year : 2010  |  Volume : 20  |  Issue : 1  |  Page : 43-47
 

ANCA negative pauci-immune glomerulonephritis with systemic involvement


Department of Nephrology, Meenakshi Mission Hospital and Research Centre, Madurai - 625 107, India

Date of Web Publication29-Mar-2010

Correspondence Address:
K Sampathkumar
Meenakshi Mission Hospital and Research Centre, Melur Road, Madurai - 625 107
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0971-4065.62096

Rights and Permissions

  Abstract 

Systemic vasculitides (SV) are a group of diseases with multi system involvement and varied clinical presentation. Anti-neutrophil cytoplasmic antibody (ANCA) testing has high sensitivity and specificity for SV. We describe the clinical course of four patients who had pauci-immune glomerulonephritis with systemic involvement without serological ANCA positivity; they were followed up for a cumulative 55 patient months. The mean Birmingham vasculitis score score was 23. All four had systemic symptoms with arthralgias and fever (100%). Neurological manifestations were seen in two patients (66%). Accelerated hypertension was seen in one. One patient had pulmonary renal syndrome. Renal manifestation was characterized by nephrotic range of proteinuria with glomerular hematuria in all (100%) and severe renal failure requiring dialysis in three (66%). At admission the mean blood urea was 146 ± 19 mg% and mean serum creatinine was 5.6 ± 1.9 mg%. Renal biopsy revealed focal proliferative glomerulonephritis with crescents only in 20-30% of glomeruli. There was significant chronic interstitial involvement in two patients (66%). Therapy with pulse steroids, cyclophosphamide, and mycophenolate mofetil (MMF) was effective in three patients while one died with lung hemorrhage. In conclusion, majority of patients with ANCA negative pauci-immune glomerulonephritis have multi-system involvement at admission. Renal biopsy is characterized by focal proliferative lesions with crescents and significant chronic interstitial fibrosis. Immunosuppressive drugs in the form of corticosteroids, MMF and cyclophosphamide bring about marked renal recovery in most patients.


Keywords: Anti-neutrophil cytoplasmic antibody, rapidly progressive glomerulonephritis, renal failure


How to cite this article:
Sampathkumar K, Ramakrishnan M, Sah A K, Gowtham S, Ajeshkumar R N. ANCA negative pauci-immune glomerulonephritis with systemic involvement. Indian J Nephrol 2010;20:43-7

How to cite this URL:
Sampathkumar K, Ramakrishnan M, Sah A K, Gowtham S, Ajeshkumar R N. ANCA negative pauci-immune glomerulonephritis with systemic involvement. Indian J Nephrol [serial online] 2010 [cited 2020 Aug 3];20:43-7. Available from: http://www.indianjnephrol.org/text.asp?2010/20/1/43/62096



  Introduction Top


Pauci-immune crescentic necrotizing glomerulonephritis (GN) is defined clinically by rapidly progressive glomerulonephritis and histologically by the presence of focal glomerular necrosis and extracapillary proliferation in the absence of significant glomerular immune deposits. In 1982, Davies et al. described for the first time autoantibodies directed against neutrophil cyctoplasmic targets. [1] Later Van der Waude et al. published their work in Wegener's granulomatosis, wherein auto antibodies were described against ethanol fixed neutrophils. [2] This was followed by the work of Falk and Jennette on patients with microscopic polyangitis, in whom perinuclear staining pattern of auto antibodies was described. [3] The presence of either PR3-anti-neutrophil cytoplasmic antibody (ANCA) (proteinase 3) or MPO-ANCA (Myeloperoxidase) proved in a meta analysis by Rao et al. and an European study by Hagen et al. to have a sensitivity of 91% and specificity of 98% for active pauci immune vasculitis/glomerulonephritis. [4],[5] In 10% of the cases with systemic vasculitis, ANCA is negative. Only few case series describe the clinical profile of this group. Here we discuss the clinical presentation of four cases of systemic vasculitis with negative serology for ANCA. Disease activity at initial clinical presentation was evaluated by using the Birmingham vasculitis assessment score (BVAS). [6] This scoring system consists of a list of items that are based on clinical history and physical examination supported by laboratory data of patients with systemic vasculitis.


  Case Reports Top


Case 1

A 62-year-old male presented with hematuria, oliguria, and arthralgia of three weeks duration with renal impairment. He had a renal biopsy done one week ago elsewhere, which revealed mild mesangial proliferation with acute tubular necrosis. He was started on hemodialysis. Serological testing was not done at that time. There was no recovery after four weeks, following which he was referred here. Two days prior to admission he developed seizures with fever. At admission his blood pressure was 160/100 mm Hg. Serology for auto antibodies was negative as shown in [Table 1]. Serum complement levels were normal. He was treated by hemodialysis and a repeat renal biopsy was performed in our center which showed focal glomerular tuft infiltration by neutrophils. 20% of the glomeruli showed crescents. IF was negative for immunoglobulin deposits. It is likely that the initial biopsy had missed the glomerular crescents due to their focal nature. He was treated with three intravenous methyl prednisolone, each of 1 gram pulse, followed by oral cyclophosphamide therapy in a dose of 2 mg/kg/day which was continued for 12 weeks. His renal failure resolved after four weeks. The patient was switched to mycophenolate mofetil (MMF) at a dose of 1.5 gram/d. When he attained a sustained clinical remission the dose of MMF was reduced to 500 mg once a day. However, he developed a relapse twelve months later with renal failure requiring dialysis. MMF was again restored to 1.5 gm per day and his renal function improved after two weeks. He is currently on follow-up with serum creatinine level of 1.3 mg% with normal urinalysis.

Case 2

A-52-year-old man presented with two weeks history of fever associated with arthralgia, cough with recurrent hemoptysis, and oliguria. Chest X-ray showed multiple thin walled cavities in both lungs [Figure 1]. Investigations are shown in [Table 1]. Serology for auto antibodies was negative as shown. Renal biopsy showed pauciimmune crescentic glomerulonephritis with 50% crescents. The IF was negative for immunoglobulin deposits. He was treated with pulse methyl prednisolone and oral cyclophosphamide. He died within four weeks of admission with severe pulmonary hemorrhage.

Case 3

A seven-year-old girl was admitted with two weeks history of fever, headache, and puffiness of face. Physical findings revealed severe hypertension (210/120 mm Hg) with left sided Bell's palsy. Investigations showed proteinuria, glomerular hematuria, and renal failure [Table 1]. Serology for auto antibodies was negative as shown in [Table 1]. Serum complement levels were normal. Renal biopsy showed significant chronic tubulointerstitial changes with focal crescents. The IF was negative for immunoglobulin deposits [Figure 2]. She was started on pulse methyl prednisolone along with cyclophosphamide, which was switched over to mycophenolate mofetil after eight weeks. Her renal function has stabilized with a serum creatinine level of 1.8 mg. However, she requires four different classes of anti hypertensive drugs for control of blood pressure. Currently, she is on follow-up for the past 16 months.

Case 4

A 36-year-old male was admitted with one month history of fatigue, fever, and arthralgias, which was followed by oliguria for one week. His blood pressure at admission was 150/100 mm Hg. Urinalysis showed high protein creatinine ratio with glomerular hematuria. He was in severe renal failure and underwent hemodialysis. Serology for auto antibodies was negative as shown in [Table 1]. Serum complement levels were normal. A percutaneous renal biopsy revealed 89% of the glomeruli had cellular crescents and focal fibrinoid necrosis with intact tubulointerstitium.The IF was negative for immunoglobulin deposits. He was started on pulse intravenous methyl prednisolone and cyclophosphamide.After eight weeks his renal function improved and is creatinine is currently 2.4 mg%. His current immunosuppression consists of MMF (1 G/day) along with 0.5 mg/kg/day of prednisolone.


  Discussion Top


ANCA are antibodies to human neutrophil cytoplasmic granule proteins. There are two main types of ANCA pattern that can be discerned on the basis of indirect immunofluorescence (IIF) on ethanol-fixed human neutrophils, namely cytoplasmic or cANCA staining, and perinuclear or pANCA staining. The main antigens involved the staining patterns are protease 3 (PR3), which closely correlates with the cANCA Indirect Immunoflourescense pattern, and myeloperoxidase (MPO), which is responsible for the majority of pANCA patterns. International consensus guidelines recommend all sera are first tested by IIF, and subsequently by ELISA for PR3 and MPO if the IIF is positive. We tested our patients for IIF followed by anti MPO and PR-3 antibodies and they were negative. There is a wealth of literature on the ANCA positive systemic vasculitis with regards to clinical presentation, pathogenesis, pathology and treatment. But, approximately 10% of systemic vasculitis patients test negative for ANCA. This group has been studied only infrequently. Hedger et al. investigated 35 patients with ANCA-negative rapidly progressive glomerulonepritis and found that they had fewer airway symptoms than ANCA-positive ones but failed to find any other difference between these two subgroups of patients. [7] In a multicentric retrospective observational study Eisenberger et al. have identified 20 cases with ANCA negative vasculitis. [8] The renal histology revealed a high percentage of active glomerular lesions (50%), mainly cellular crescents, whereas only 28% of them had glomerular necrosis. Chronic tissue damage with glomerulosclerosis (21%) and diffuse interstitial fibrosis (40%) were already present at diagnosis, more prominent than in historical ANCA positive patients. This has been our observation also that chronic interstitial fibrosis is already present even though the history of the clinical illness is relatively short.

Another recent study from China analyzed patients with ANCA negative vasculitis. [9] Clinical and pathologic characteristics were compared between patients with and without ANCA. Among the 85 patients with pauci-immune GN, 28 (32.9%) were ANCA negative. Compared with the 57 ANCA-positive patients, the ANCA-negative patients were much younger. The level of urinary protein and the prevalence of nephrotic syndrome were significantly higher in ANCA-negative patients than that in ANCA-positive patients. This has been our observation also that nephrotic range of proteinuria is common in ANSV. However, the prevalence of extrarenal involvement was significantly lower in ANCA-negative patients. The renal pathology was more severe in ANCA negative groups and the renal survival was poorer.

At variance with the published series, our patients had prominent extra renal manifestations in the form of arthralgia, fever, seizures, mono neuritis and lung involvement. The first case presented with predominant renal involvement. The second case had pulmonary renal syndrome while the third case had renal and facial nerve involvement. Renal biopsy showed pauciimmune state with cellular crescents in all the cases. Glomeruli showed focal proliferative lesions with neutrophilic infiltrates. However necrotic lesions in the glomeruli were rare. There was a significant interstitial fibrosis in two cases. Response to immunosuppressive treatment was excellent in three patients while the one with pulmonary involvement succumbed to the disease. Among the systemic vasculitides Classic polyarteritis nodosa (PAN) patients do not have circulating ANCA. However, classic PAN commonly presents with renal infarction with minor degrees of proteinuria due to medium vessel involvement. In contrast our patients had nephrotic range of proteinuria with crescents. Churg-Strauss syndrome has the lowest positivity rate for ANCA (< 5% for PR3-ANCA and 40% for MPO-ANCA). [10],[11] However, none of our patients had eosinophilia or tissue eosinophil infiltrates.

Age has important bearing on the prognosis of ANCA negative systemic vasculitis. In Ute Eisenberger's series age above 65 years was associated with high mortality. The age group in our series is considerably younger with none of the patients above 65 years of age. Secondly, our patients have fared better due to the fact that MMF was used more often. MMF is increasingly being found useful in the induction and remission phases of systemic vasculitides. [12] In another study 32 consecutive patients with 34 episodes of active vasculitis who could not be treated with cyclophosphamide were followed up after starting therapy with MMF. Complete remission (CR) was obtained in 25 (78%) patients, partial remission (PR) in 6 (19%), whereas 1 (3%) patient did not respond. [13] In a study comparing cyclophosphamide to MMF in Chinese patients with paucimmune vasculitis and moderate renal involvement, it was shown that MMF was superior in inducing remission (77% versus 47% in cyclophosphamide group). 44% of MMF treated group recovered normal renal function against 15% in the cyclophosphamide group. [14]

It is becoming increasingly clear by human and experimental data that ANCAs are not only diagnostic markers but pathogenetically linked to vasculitic process too. Described briefly, neutrophils are primed by TNF - alpha and express cell surface MPO and PR-3Subsequent interaction with ANCA leads on to endothelial damage and transmigration of neutrophils and their degranulation with resultant necrotizing vasculitis. [15] Anti-endothelial cell antibodies (AECA) have been implicated to have a causal role in ANCA negative vasculitis. In a study involving sera from 19 patients with ANCA negative glomerulonephritis, 10 were positive for AECA. In ANCA-negative pauci-immune GN, 10 of 19 patients were serum IgG-AECA positive and seven bands reactive with endothelial antigens could be blotted. The prevalence of skin rash and thrombocytosis was significantly higher in patients with anti-76 kDa and anti-123 kDa AECA autoantibodies than in patients without, respectively. BVAS of patients with anti-200 kDa AECA were significantly higher than in patients without ANCA positivity. [16] Another newly investigated marker is Circulating Angiopoietin-2 which is elevated and closely correlates with BVAS in systemic vasculitides with renal involvement. Angiopoietin-2 might be a potential mediator of endothelial cell detachment. [17] An intrinsic podocyte defect may also be operative. In a conditional knock out mouse model specific podocyte deletion of VHL gene (Von Hippel-Lindau gene) has been shown to lead on to crescentic glomerulonephritis without ANCA positivity. VHL protein product interacts with hypoxia-inducible factor 1 (HIF-1) whose targets include tumour necrosis factor-a (TNF-a), vascular endothelial growth factor-A (VEGF-A), the chemokine receptor 4 (CXC-R4) all of which are implicated in the glomerular damage due to vasculitis. [18]


  Conclusion Top


Patients who present with ANCA negative vasculitis with pauci immune glomerulonephritis have significant systemic involvement. Renal lesions are characterized by focal proliferation with crescents associated with chronic tubulointerstitial changes. Immunosuppressive drugs in the form of corticosteroids, cyclophosphamide, and MMF bring about significant improvement in prognosis. Further research is needed to elucidate the pathogenesis and focus on specific diagnostic markers for this group.

 
  References Top

1.Davies DJ, Moran JE, Niall JF, Ryan GB. Segmental necrotizing glomerulonephritis with anti neutrophil antibody: possible arbovirus aetiology. Br Med J 1982;285:606.  Back to cited text no. 1      
2.van der Woude FJ, Rasmussen N, Lobatto S, Wiik A, Permin H, van Es LA, et al. Autoantibodies to neutrophils and monocytes: A new tool for diagnosis and a marker of disease activity in Wegener's granulomatosis. Lancet 1985;23:425-9.  Back to cited text no. 2      
3.Falk RJ, Jennette JC. Anti neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Eng J Med 1988;318:1651.  Back to cited text no. 3      
4.Rao JK, Weinberger M, Oddone EZ, Allen NB, Landsman P, Feussner JR. The role of antineutrophil cytoplasmic antibody Testing in the diagnosis of Wegener's granulomatosis. Ann Int Med 1995;123:925-32.  Back to cited text no. 4      
5.Hagen EC, Daha MR, Hermans J, Andrassy K, Csernok E, Gaskin G, et al. Diagnostic value of standardized assays for anti neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR project for ANCA assay standardization. Kidney Int 1998;53:743-53.  Back to cited text no. 5      
6.Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. Q J Med 1994;87:671-8.  Back to cited text no. 6      
7.Hedger N, Stevens J, Drey N, Walker S, Roderick P. Incidence and outcome of pauci-immune rapidly progressive glomerulonephritis in Wessex, UK: A 10-year retrospective study. Nephrol Dial Transplant 2000;15:1593-9.  Back to cited text no. 7      
8.Eisenberger U, Fakhouri F, Vanhille P, Beaufils H, Mahr A, Guillevin L, et al. ANCA-negative pauci-immune renal vasculitis: Histology and outcome. Nephrol Dial Transplant 2005;20:1392-9.  Back to cited text no. 8      
9.Chen M, Yu F, Wang SX, Zou WZ, Zhao MH, Wang HY. Antineutrophil cytoplasmic autoantibody-negative pauci-immune crescentic glomerulonephritis. J Am Soc Nephrol 2007;18:599-605.  Back to cited text no. 9      
10.Sablé-Fourtassou R, Cohen P, Mahr A, Pagnoux C, Mouthon L, Jayne D, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005;143:632-8.  Back to cited text no. 10      
11.Chemmalakuzhy AJ, Zhou XJ, Hedayati SS; Medscape. ANCA-negative glomerulonephritis associated with nonasthmatic churg-strauss syndrome. Nat Clin Pract Nephrol 2008;4:568-74.  Back to cited text no. 11      
12.Joy MS, Hogan SL, Jennette JC, Falk RJ, Nachman PH. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Arthritis Rheum 2005;52:262-8.  Back to cited text no. 12      
13.Stassen PM, Cohen Tervaert JW, Stegeman CA. Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis 2007;66:798-802.  Back to cited text no. 13      
14.Hu W, Liu C, Xie H, Chen H, Liu Z, Li L. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant 2008;23:1307-12.  Back to cited text no. 14      
15.Hewins P, Savage CO. ANCA and neutrophil biology. Kidney Blood Press Res 2003;26:221-5.  Back to cited text no. 15      
16.Cong M, Chen M, Zhang JJ, Hu Z, Zhao MH. Anti-endothelial cell antibodies in antineutrophil cytoplasmic antibodies negative pauci-immune crescentic glomerulonephritis. Nephrology 2007;3:228-34.  Back to cited text no. 16      
17.Kümpers P, Hellpap J, David S, Horn R, Leitolf H, Haller H, et al. Circulating angiopoietin-2 is a marker and potential mediator of endothelial cell detachment in ANCA-associated vasculitis with renal involvement. Nephrol Dial Transplant 2009;24:1845-50.  Back to cited text no. 17      
18.Ding M, Cui S, Li C, Jothy S, Haase V, Steer BM, et al. Loss of the tumour suppressor Vhlh leads to upregulation of Cxcr4 and rapidly progressive glomerulonephritis in mice. Nat Med 2006;12:1081-7.  Back to cited text no. 18      


    Figures

  [Figure 1], [Figure 2]
 
 
    Tables

  [Table 1]

This article has been cited by
1 Pulmonary-Renal Syndrome with Negative ANCAs and Anti-GBM Antibody
Hiroshi Yamaguchi,Atsuhisa Shirakami,Takashi Haku,Takashige Taoka,Yoshikazu Nakanishi,Toru Inai,Takanori Hirose
Case Reports in Nephrology. 2013; 2013: 1
[Pubmed] | [DOI]
2 Implication rénale subclinique dans la vascularite cryoglobulinémique essentielle et la périartérite noueuse classique
Tamer A. Gheita,Nermeen A. Khairy,Mohamed Nasr-Allah,Hani Hussein
Revue du Rhumatisme. 2012; 79(3): 215
[Pubmed] | [DOI]
3 Subclinical renal involvement in essential cryoglobulinemic vasculitis and classic polyarteritis nodosa
Gheita, T.A., Khairy, N.A., Nasrallah, M.M., Hussein, H.
Joint Bone Spine. 2012; 79(3): 274-280
[Pubmed]
4 Subclinical kidney involvement in essential cryoglobulinemic vasculitis and classic polyarteritis nodosa | [Implication rénale subclinique dans la vascularite cryoglobulinémique essentielle et la périartérite noueuse classique]
Gheita, T.A., Khairy, N.A., Nasr-Allah, M., Hussein, H.
Revue du Rhumatisme (Edition Francaise). 2012; 79(3): 215-221
[Pubmed]
5 Subclinical renal involvement in essential cryoglobulinemic vasculitis and classic polyarteritis nodosa
Tamer A. Gheita,Nermeen A. Khairy,Mohamed M. Nasrallah,Hani Hussein
Joint Bone Spine. 2012; 79(3): 274
[Pubmed] | [DOI]



 

Top
Print this article  Email this article
Previous article Next article

    

© Indian Journal of Nephrology
Published by Wolters Kluwer - Medknow
Online since 20th Sept '07